 |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
U.S.
Genomics renames to Pathogenetix, raises $1.3M
U.S. Genomics, a pathogen-diagnostic technologies firm in Woburn, has changed its name to Pathogenetix Inc. The name change was noted in a regulatory filing with the U.S. Securities and Exchange Commission, in which the company reported it had raised $1.3 million in an equity offering and converted $900,000 in debt.
Pathogenetix does not yet have a working website and the U.S. Genomics website and phone number were down, as of Friday morning. David Hoey, vice president of business development at the company, said by phone that the disruptions were temporary and due to a company move within its Woburn site.
“The reason we changed the name is the company is focused on pathogen detection,” Hoey said. Previous work conducted by U.S. Genomics included development of products to sequence DNA, in addition to its work to develop biosensors and diagnostics for pathogens, which it had deployed through government agencies.
The regulatory filing for the $1.3 million equity offering does not indicate who the four unnamed investors are, but on its list of related persons it does include board members Augustine Lawlor, a partner with Healthcare Ventures in Cambridge; Enrico Petrillo, a partner with CB Health Ventures in Boston; and Stephen Gullans, a managing director at Excel Venture Management.
The $900,000 notes conversion, included in a second regulatory filing, is part of a planned $1.2 million debt offering.
Prior to its name change, U.S. Genomics was founded by brothers Eugene Chan and Ian Chan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|